Results 91 to 100 of about 46,872 (214)

SGLT2 Inhibitors for Cardioprotection

Oman Medical Journal, 2023
Sulthan Al Rashid, P. Elango, Syed Ziaur Rahman   +2 more
openaire   +3 more sources

Intestinal absorption of glucose in mice as determined by positron emission tomography. [PDF]

, 2018
KEY POINTS:The goal was to determine the importance of the sodium-glucose cotransporter SGLT1 and the glucose uniporter GLUT2 in intestinal glucose absorption during oral glucose tolerance tests (OGTTs) in mice.
Bindslev, Casteleyn, Chow, Debnam, Gallo, Ghezzi, Ghezzi, Gorboulev, Grundy, Guillam, Hediger, Holst, Hummel, James, Kayano, Kellett, Kellett, Kreissl, Kuhre, Loening, Madunic, Mudie, Powell, Rizza, Roder, Sala-Rabanal, Santer, Schmitt, Stumpel, Suckow, Thorens, Thorens, Wong, Wright, Wright, Yamashita, Yu, Yu   +37 more
core   +1 more source

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure
Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
doaj   +1 more source

The Na+/glucose cotransporters: from genes to therapy [PDF]

, 2010
Glucose enters eukaryotic cells via two types of membrane-associated carrier proteins, the Na+/glucose cotransporters (SGLT) and the facilitative glucose transporters (GLUT). The SGLT family consists of six members.
DAVID-SILVA, A., FREITAS, H.S., MACHADO, U.F., MORI, R.C., OKAMOTO, M.M., SABINO-SILVA, R.   +5 more
core   +2 more sources

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature

Quality in Sport
• The purpose of research: Heart failure (HF) is an important global health concern. Despite advancements in treatment, HF remains the leading cause of hospitalization among the elderly.
Silvia Ciraolo, Agnieszka Kulczycka-Rowicka, Joanna Wojda, Katarzyna Lesiczka-Fedoryj, Anna Walczak, Zuzanna Kościuszko, Adam Sobiński, Matylda Czerwonka, Katarzyna Kurza, Julianna Podolec   +9 more
doaj   +1 more source

SGLT2 Inhibitors in Liver Patients [PDF]

Clinical Gastroenterology and Hepatology, 2020
John Chen Hsiang, Vincent Wai-Sun Wong
openaire   +2 more sources

Recommendations on the Proper Use of SGLT2 Inhibitors

Journal of Diabetes Investigation, 2020
The Committee on the Proper Use of SGLT2 Inhibitors
doaj   +1 more source

The Impact of Different Antidiabetic Drugs on Fracture Risk in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials With a Focus on SGLT2 Inhibitors

American Journal of Medicine Open
SGLT2 inhibitors are a new class of antidiabetic drugs that have shown cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease. However, their effects on fracture risk are unclear and may depend on the type and
Bushra Admani, MBBS, Fizza Zehra Raza, MBBS, Fatima Siddiqui, MBBS, Muhammad Talal Ashraf, MBBS, Muhammad Khuzzaim Khan, MBBS, Ifra Habib, MBBS, Ayesha Usman, MBBS, Bareeha Mansoor, MBBS, Zaira Nadeem, MBBS, Rana Jahanzeb Ghaffer, MBBS, Muhammad Riyyan, MBBS, Sawaira Sajid, MBBS, Muhammad Hassan Ali Chania, MBBS, Mahnoor Saleem, MBBS, Saad Javaid, MBBS, Nikhil Duseja, MBBS, Hussam Al Hennawi, MD, Sunita Lakhani, MD   +17 more
doaj   +1 more source

SGLT2 Inhibitors in ADPKD

Journal of the American Society of Nephrology
Abstract Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a leading cause of kidney failure worldwide. Disease progression is driven by cyst expansion, tubular injury, and maladaptive metabolic and hemodynamic changes.
Marie Therese Bou Antoun, Abdul Hamid Borghol, Levon Souvalian, Mohamad Hadla, Georges Abboud, Ahmad Ghanem, Fadi George Munairdjy Debeh, Jean Marc Mardirossian, Mahdi Salih, Pranav S. Garimella, Volker Vallon, Fouad T. Chebib   +11 more
openaire   +1 more source

Time-varying cost-effectiveness analysis of sodium-glucose cotransporter-2 inhibitors in Chinese patients with heart failure and reduced ejection fraction: A microsimulation of the real-world population

Frontiers in Pharmacology
ObjectiveSodium-glucose cotransporter-2 (SGLT2) inhibitors showed time-varying effects in heart failure and reduced ejection fraction (HFrEF), but corresponding cost-effectiveness in different timeframes remained poorly understood.
Xinyu Zou, Xingchen He, Qingyang Shi, Qingyang Shi, Si Wang, Nan Li, Yiling Zhou, Yiling Zhou, Ming Hu, Li Luo, Yiwen Shen, Ye Zhu, Chim C. Lang, Zhiming Zhu, Haoming Tian, Sheyu Li   +15 more
doaj   +1 more source